-
公开(公告)号：US08716446B2
公开(公告)日：2014-05-06
申请号：US12589511
申请日：2009-08-21
申请人： Yuni Jung , Seong-Hyun Ho , Myung-Ok Park , Myoung-Suk Kim
发明人： Yuni Jung , Seong-Hyun Ho , Myung-Ok Park , Myoung-Suk Kim
CPC分类号： C07K14/5431 , A61K38/00 , A61K47/10 , C07K2319/31
摘要： The present invention provides for biopolymer conjugates of an IL-11 analog (mIL-11) and a biocompatible polymer. The mIL-11 of the invention displays an enhanced resistance to acidolysis and shows increased stability as compared to rhIL-11. The conjugates of the present invention are characterized by a longer serum half-life and exhibit essentially no loss of activity as compared to the corresponding unconjugated mIL-11.
摘要翻译： 本发明提供了IL-11类似物（mIL-11）和生物相容性聚合物的生物聚合物缀合物。 与rhIL-11相比，本发明的mIL-11显示出增强的酸解耐性并且显示增加的稳定性。 本发明的缀合物的特征在于较长的血清半衰期，与相应的未结合的mIL-11相比基本上没有活性损失。
-
公开(公告)号：US20100098658A1
公开(公告)日：2010-04-22
申请号：US12589511
申请日：2009-08-21
申请人： Yuni JUNG , Seong-Hyun Ho , Myung-Ok Park , Myoung-Suk Kim
发明人： Yuni JUNG , Seong-Hyun Ho , Myung-Ok Park , Myoung-Suk Kim
CPC分类号： C07K14/5431 , A61K38/00 , A61K47/10 , C07K2319/31
摘要： The present invention provides for biopolymer conjugates of an IL-11 analog (mIL-11) and a biocompatible polymer. The mIL-11 of the invention displays an enhanced resistance to acidolysis and shows increased stability as compared to rhIL-11. The conjugates of the present invention are characterized by a longer serum half-life and exhibit essentially no loss of activity as compared to the corresponding unconjugated mIL-11.
摘要翻译： 本发明提供了IL-11类似物（mIL-11）和生物相容性聚合物的生物聚合物缀合物。 与rhIL-11相比，本发明的mIL-11显示出增强的酸解耐性并且显示增加的稳定性。 本发明的缀合物的特征在于较长的血清半衰期，与相应的未结合的mIL-11相比基本上没有活性损失。
-
3.发明申请Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same 审中-公开生物活性物质与生物相容性聚合物与1：1络合物结合，其制备方法和包含其的药物组合物公开(公告)号：US20070117924A1
公开(公告)日：2007-05-24
申请号：US11655673
申请日：2007-01-19
申请人： Myung-Ok Park
发明人： Myung-Ok Park
IPC分类号： A61K47/48
CPC分类号： A61K47/60
摘要： The present invention relates to conjugates of biocompatible polymers and biologically active molecules wherein the activated biocompatible polymer is conjugated to a carboxyl group of biologically active material at a molar ratio of 1:1 and methods of preparation thereof and a pharmaceutical composition comprising the same.
摘要翻译： 本发明涉及生物相容性聚合物和生物活性分子的缀合物，其中活化的生物相容性聚合物以1：1的摩尔比与生物活性物质的羧基缀合，并且其制备方法和包含其的药物组合物。
-
4.发明申请Pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis 失效包含用于抑制血管发生的精氨酸脱亚氨酶的药物组合物公开(公告)号：US20060002915A1
公开(公告)日：2006-01-05
申请号：US11159428
申请日：2005-06-20
申请人： Bon-Hong Min , Myung-Ok Park , Min-Young Kim , Byung-Young Park , Boe-Gwun Chun , Sang-Wook Kang , Chang-Hee Moon
发明人： Bon-Hong Min , Myung-Ok Park , Min-Young Kim , Byung-Young Park , Boe-Gwun Chun , Sang-Wook Kang , Chang-Hee Moon
CPC分类号： A61K38/50 , C12Y305/03006
摘要： The present invention relates to a pharmaceutical composition for inhibiting angiogenesis which comprises arginine deiminase as an active ingredient, where the arginine deiminase, obtained from Mycoplasma arginini or prepared by a genetic recombination technique, may be conjugated to an activated polymer to lower its immunogenecity and increase its life time. The pharmaceutical composition of the present invention exhibits an excellent inhibitory activity against angiogenesis.
摘要翻译： 本发明涉及一种抑制血管发生的药物组合物，其包含精氨酸脱亚氨酶作为活性成分，其中由支原体支原体获得或通过遗传重组技术制备的精氨酸脱亚胺酶可与活化的聚合物缀合以降低其免疫原性并增加 它的生活时间。 本发明的药物组合物显示出优异的血管生成抑制活性。
-
5.发明申请CATIONIC LIPIDS, METHODS FOR PREPARING THE SAME, AND DELIVERY SYSTEMS HAVING ABILITY TO TRANSITION INTO CELLS COMPRISING THE SAME 审中-公开阳离子脂肪酸，其制备方法以及具有能够转化成包含其的细胞的能力的递送系统公开(公告)号：US20130123485A1
公开(公告)日：2013-05-16
申请号：US13810650
申请日：2011-07-12
申请人： Myung-Ok Park , Eun Young Yoon
发明人： Myung-Ok Park , Eun Young Yoon
IPC分类号： C07K5/06 , C07C233/47
CPC分类号： C07K5/06 , A61K9/1271 , A61K9/1272 , C07C233/31 , C07C233/35 , C07C233/47 , C07H13/04
摘要： The present invention provides cationic lipids, methods for preparing the same, and delivery systems comprising the same. The present invention can provide cationic lipids which enhance the efficiency of intracellular or in vivo delivery of multiple-anionic target compounds such as drugs, anticancer agents, nucleic acids, etc., have no intracellular toxicity, but show increased stability, methods for preparing the same, and delivery systems comprising the same.
摘要翻译： 本发明提供阳离子脂质，其制备方法和包含其的递送系统。 本发明可以提供阳离子脂质，其提高细胞内或体内递送多阴离子靶化合物如药物，抗癌剂，核酸等的效率，没有细胞内毒性，但显示出增加的稳定性，制备方法 相同的，以及包括它们的递送系统。
-
公开(公告)号：US20050281778A1
公开(公告)日：2005-12-22
申请号：US11187522
申请日：2005-07-22
申请人： Myung-Ok Park , John Jacobs
发明人： Myung-Ok Park , John Jacobs
摘要： The present invention relates to conjugates of biocompatible polymers and hGH, particularly PEG-hGH, where the activated biocompatible polymer is conjugated to a carboxyl group of hGH at a molar ratio of 1:1, methods of preparation, and related pharmaceutical compositions. The PEG-hGH conjugates have up to 20% of the activity of the native hGH while the in vivo half life is increased 10 fold. The PEG-hGH conjugates may be used therapeutically to treat growth retardation or growth failure, especially short stature in children, and conditions related to aging.
摘要翻译： 本发明涉及生物相容性聚合物和hGH，特别是PEG-hGH的缀合物，其中活化的生物相容性聚合物以1：1的摩尔比与hGH的羧基缀合，制备方法和相关药物组合物。 PEG-hGH缀合物具有高达天然hGH活性的20％，而体内半衰期增加10倍。 PEG-hGH缀合物可用于治疗生长迟缓或生长衰竭，特别是儿童身材矮小以及与老化有关的病症。
-
公开(公告)号：US08431543B2
公开(公告)日：2013-04-30
申请号：US12522215
申请日：2008-01-07
申请人： Myung-Ok Park , Yu-Kyoung Oh , Sang Myoung Noh , Sung Sik Bang , Myung Suk Kim
发明人： Myung-Ok Park , Yu-Kyoung Oh , Sang Myoung Noh , Sung Sik Bang , Myung Suk Kim
CPC分类号： C12N15/87 , A61K9/5161 , A61K47/36
摘要： The present invention relates to a conjugate of chitosan and polyamine polymer that is useful for transferring a desired gene medicine into cells, and a method for preparing the same. In particular, the present invention relates to a double conjugate that is prepared by 1 in king poly-L-arginine to low molecular weight chitosan or triple conjugate that is prepared by additionally linking polyethylene glycol (PEG) to the double conjugate, and a method for preparing the same. The chitosan based cationic polymer conjugate of the present invention forms a complex with negatively charged gene medicine such as plasmid DNA and small interfering RNA to efficiently transfer the desired gene medicine into cells with low cytotoxicity. Accordingly, the conjugate can be used as an effective delivery system for in vivo administration of gene medicine.
摘要翻译： 本发明涉及可用于将期望的基因药物转移到细胞中的壳聚糖和多胺聚合物的缀合物及其制备方法。 特别地，本发明涉及通过将聚乙二醇（PEG）与双重缀合物另外连接而制备的由聚异丁酰胺聚合物1中的1与低分子量壳聚糖或三重缀合物制备的双重缀合物， 为准备相同。 本发明的基于壳聚糖的阳离子聚合物缀合物与带负电荷的基因药物如质粒DNA和小干扰RNA形成复合物，以有效地将期望的基因药物转移到具有低细胞毒性的细胞中。 因此，缀合物可以用作体内施用基因药物的有效递送系统。
-
公开(公告)号：US20060134736A1
公开(公告)日：2006-06-22
申请号：US11314926
申请日：2005-12-20
申请人： John Jacobs , Shiliang Qin , Mingyu Zhang , Huaina Li , Myung-Ok Park
发明人： John Jacobs , Shiliang Qin , Mingyu Zhang , Huaina Li , Myung-Ok Park
摘要： The present invention relates to conjugates of biocompatible polymers and hGH, particularly PEG-hGH, where the activated biocompatible polymer is conjugated to a carboxyl group of hGH at a molar ratio of 2:1 or less, preferably 1:1, methods of preparation, and related pharmaceutical compositions. The PEG-hGH conjugates have up to 20% of the activity of the native hGH while the in vivo half life is increased 10 fold. The PEG-hGH conjugates may be used therapeutically to treat growth retardation or growth failure, especially short stature in children, and conditions related to aging.
摘要翻译： 本发明涉及生物相容性聚合物和hGH，特别是PEG-hGH的缀合物，其中活化的生物相容性聚合物以2:1或更低，优选1：1的摩尔比与hGH的羧基缀合，制备方法， 和相关的药物组合物。 PEG-hGH缀合物具有高达天然hGH活性的20％，而体内半衰期增加10倍。 PEG-hGH缀合物可用于治疗生长迟缓或生长衰竭，特别是儿童身材矮小以及与老化有关的病症。
-
9.发明申请Biologically active material conjugated with biocompatible polymer with 1:1 complex, preparation method thereof and pharmaceutical composition comprising the same 审中-公开生物活性物质与生物相容性聚合物与1：1络合物结合，其制备方法和包含其的药物组合物公开(公告)号：US20050059129A1
公开(公告)日：2005-03-17
申请号：US10947513
申请日：2004-09-22
申请人： Myung-Ok Park
发明人： Myung-Ok Park
CPC分类号： A61K47/60
摘要： The present invention relates to conjugates of biocompatible polymers and biologically active molecules wherein the activated biocompatible polymer is conjugated to a carboxyl group of biologically active material at a molar ratio of 1:1 and methods of preparation thereof and a pharmaceutical composition comprising the same.
摘要翻译： 本发明涉及生物相容性聚合物和生物活性分子的缀合物，其中活化的生物相容性聚合物以1：1的摩尔比与生物活性物质的羧基缀合，并且其制备方法和包含其的药物组合物。
-
10.发明授权Nasal transmucosal delivery of peptide conjugated with biocompatible polymers 失效与生物相容性聚合物缀合的肽的鼻粘膜递送公开(公告)号：US06506730B1
公开(公告)日：2003-01-14
申请号：US09639483
申请日：2000-08-15
申请人： Kang Choon Lee , Myung-Ok Park
发明人： Kang Choon Lee , Myung-Ok Park
IPC分类号： A61K3809
CPC分类号： A61K38/09 , A61K9/0043 , A61K38/00 , A61K38/23 , A61K38/25 , A61K38/29 , A61K47/56 , A61K47/60
摘要： The present invention relates to a pharmaceutical composition for the nasal transmucosal delivery of a biocompatible polymer-biologically active peptide conjugate. The pharmaceutical composition of the present invention increases the water solubility of peptide, which is sparingly soluble in water, improves its stability by protecting it from being degraded by proteases. As a result, the number of administrations of the drug and the side-effects induced by drug abuse are decreased. In addition, since the pharmaceutical composition of the present invention is delivered through the nasal cavity, it allows drug activity to be expressed in a short period of time and improves a bioavailability.
摘要翻译： 本发明涉及用于经鼻粘膜递送生物相容性聚合物 - 生物活性肽缀合物的药物组合物。 本发明的药物组合物增加了微溶于水的肽的水溶性，通过保护其免受蛋白酶降解而提高其稳定性。 因此，药物滥用的药物和副作用的数量减少。 此外，由于本发明的药物组合物通过鼻腔输送，所以其允许在短时间内表达药物活性并提高生物利用度。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.023 秒)
